ArticleThe Journal of clinical endocrinology and metabolism2015
Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation.
Article in The Journal of clinical endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 103 citations in OpenAlex.
- Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.Langenbeck's archives of surgery · 2019Trial
- Vitamin D Supplementation in Primary Hyperparathyroidism: Analysis of Benefits and Hazards.Nutrients · 2026Review
- Primary hyperparathyroidism presenting as atraumatic bilateral hip fractures: a case report.Journal of medical case reports · 2026Article
- Phosphate handling as a determinant of osteoporosis in primary hyperparathyroidism.Endocrine connections · 2026Article
- Renal calcifications and primary hyperpara-thyroidism in a tertiary care hospital center of North Africa: a single-center experience.Medicine and pharmacy reports · 2026Article
- Brown Tumors of Hyperparathyroidism: A 13-Year Retrospective Case Series from a Tertiary Center in South India.Journal of orthopaedic case reports · 2026Article
- Age-stratified differences in asymptomatic primary hyperparathyroidism: a single-center cohort study from 2017 to 2024.Gland surgery · 2026Article
- Low forearm bone density as a clue to suspect primary hyperparathyroidism in postmenopausal women with osteoporosis: a retrospective study.Archives of osteoporosis · 2026Article
- Hyperparathyroidism: current concepts in diagnosis and surgical treatment.Frontiers in endocrinology · 2026Review
- Biochemical Predictors and Clinical Characteristics for the Development of Cytopenia and Bone Marrow Involvement Among Patients With Primary Hyperparathyroidism.International journal of endocrinology · 2026Article
- Vitamin D in Endocrine Disorders: A Broad Overview of Evidence in Musculoskeletal, Thyroid, Parathyroid, and Reproductive Disorders.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Primary Hyperparathyroidism with Severe Vitamin D Deficiency in Chronic Kidney Disease.Internal medicine (Tokyo, Japan) · 2025Article
- Serum PTH ≥ 40 pg/mL as a Marker of Bone Fragility and Vitamin D Deficiency in Periodontitis Patients: Biochemical, Densitometric and Genetic Evidence.Biomolecules · 2025Article
- Vitamin D Metabolism and the Risk of Renal Stones: A Focus on PHPT.Metabolites · 2025Review
- Joint association of milk intake and blood 25(OH)D levels with fracture risk in postmenopausal women: 20-year follow-up data from the Japanese Population-Based Osteoporosis cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes.Endocrine reviews · 2025Review
- MicroRNA-874-3p is a Potential Contributor to Primary Hyperparathyroidism-Induced Osteoporosis.Clinical interventions in aging · 2025Article
- Bone Disease in Primary Hyperparathyroidism-Changes Occurring in Bone Metabolism and New Potential Treatment Strategies.International journal of molecular sciences · 2024Review
- Characteristics, management and outcomes of primary hyperparathyroidism from 2009 to 2021: a single centre report from South Africa.BMC endocrine disorders · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
contextVitamin D (25-hydroxyvitamin D [25OHD]) deficiency (<20 ng/mL) and insufficiency (20-29 ng/mL) are common in primary hyperparathyroidism (PHPT), but data regarding their skeletal effects in PHPT are limited.
objectiveThe objective was to evaluate the association between 25OHD levels and PHPT severity. DESIGN, SETTINGS, AND
participantsThis is a cross-sectional analysis of 100 PHPT patients with and without 25OHD insufficiency and deficiency from a university hospital setting. OUTCOME MEASURES: We measured calciotropic hormones, bone turnover markers, and bone mineral density (BMD) by dual x-ray absorptiometry.
resultsLower 25OHD was associated with some (PTH: r = -0.42; P < .0001; 1,25-dihydroxyvitamin D: r = -0.27; P = .008; serum PO4: r = 0.31; P = .002) but not all (serum/urine calcium) indicators of PHPT severity. Lower 25OHD was also associated with younger age, higher body mass index, male gender, better renal function, and lower vitamin D intake. Comparison of those with deficient (<20 ng/mL; 19%) vs insufficient (20-29 ng/mL; 35%) vs replete (≥30 ng/mL; 46%) 25OHD demonstrated more severe PHPT as reflected by higher PTH (mean ± SEM, 126 ± 10 vs 81 ± 7 vs 72 ± 7 pg/mL; P < .0001) but no difference in nephrolithiasis, osteoporosis, fractures, serum or urinary calcium, bone turnover markers, or BMD after adjustment for age and weight. In women, T-scores at the 1/3 radius were lower in those with 25OHD of 20-29 ng/mL, compared to those who were vitamin D replete (P = .048). In multiple regression modeling, 25OHD (but not PTH) was an independent predictor of 1/3 radius BMD.
conclusionVitamin D deficiency is associated with more severe PHPT as reflected by PTH levels, but effects on BMD are limited to the cortical 1/3 radius and are quite modest. These data support international guidelines that consider PHPT patients with 25OHD <20 ng/mL to be deficient. However, in this cohort with few profoundly vitamin D-deficient patients, vitamin D status did not appear to significantly impact clinical presentation or bone density.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.